Mylan Expects Decision On Duragesic Pediatric Exclusivity “Shortly”
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Robert Coury says Mylan is prepared to “counterbalance” any strategies by Johnson & Johnson that would prevent the firm from launching its fentanyl ANDA this year. FDA should be more concerned about the use of citizen petitions and other strategies that delay generic access, he says.